Skip to content

Dual therapy with asomeprazole and amoxicillin in the first-line eradication of Helicobacter pylori

Dual therapy with asomeprazole and amoxicillin in the first-line eradication of Helicobacter pylori

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17014099
Enrollment
Unknown
Registered
2017-12-22
Start date
2018-01-01
Completion date
Unknown
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Sponsors

Department of Gastroenterology, Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The patients with dyspepsia who are referred to our hospital for upper endoscopy; 2. HP RUT and W-S staining positive; 3. Never received treatment for H. pylori infection; 4. Aged 18 to 70 years; 5. Willing and available for participation this study

Exclusion criteria

Exclusion criteria: 1. Taking any drug which could influence the study results such as PPI, H2-receptor blockers, bismuth salts and antibiotics in the previous 4 weeks; 2. Gastrointestinal malignancy; 3. Zollinger-Ellison syndrome; 4. Previous gastric and esophageal surgeries; 5. Severe concomitant cardiovascular, respiratory, renal, hepatic, hematological, neurological, endocrine or psychiatric diseases; 6. History of allergy to any of the drugs used in the study; 7. Pregnancy or lactation; 8. Any other clinically significant medical condition that could increase risk of side effects.

Design outcomes

Primary

MeasureTime frame
Eradication rate;

Secondary

MeasureTime frame
Compliance;Safety;

Countries

China

Contacts

Public ContactLiya Zhou

Department of Gastroenterology, Peking University Third Hospital

zhoumed@126.com+86 15611908239

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026